title: Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
abstract: In a double-blind, placebo-controlled trial, patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) were randomly allocated to oral treatment with sparfloxacin (200 mg loading dose followed by 100 mg once daily) or amoxycillin/clavulanic acid (500 mg/125 mg tds) for a total treatment duration of 7 to 14 days. Patients were evaluable if they had a FEV1/FVC ratio of less than 70% at stable state and presented with a suspected infectious exacerbation defined as increases in dyspnoea, sputum volume and sputum purulence. The primary efficacy variable was the overall success (defined as disappearance or improvement of dyspnoea and reductions in sputum volume and purulence) at end of treatment and follow-up. Overall efficacy was assessed in both the intent-to-treat (728 patients) and the evaluable (351 patients) populations. At the end of treatment and follow-up, success rates were identical for the sparfloxacin (87.3% and 78.7%) and amoxycillin-clavulanic acid (88.8% and 79.8%) treatment groups. Similar figures were found for the intent-to-treat population. The analysis of drug safety was similar for both treatment groups. The most frequently encountered pathogens were Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Sparfloxacin appeared superior for bacteriological eradication of Haemophilus influenzae, and Moraxella catarrhalis. Sparfloxacin in a single daily dose appears at least as effective as amoxycillin/clavulanic acid in the treatment of patients with acute exacerbations of COPD.
authors: I.R.C.C.S. Ospedale Maggioze, Milan, Italy.
authors: L
authors: L
authors: Allegra
authors: N
authors: N
authors: Konietzko
authors: P
authors: P
authors: Leophonte
authors: J
authors: J
authors: Hosie
authors: R
authors: R
authors: Pauwels
authors: J N
authors: JN
authors: Guyen
authors: P
authors: P
authors: Petitpretz
mesh_terms: D000208:Acute Disease; D000658:Amoxicillin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D001936:Moraxella catarrhalis / Q000187:drug effects; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D013296:Streptococcus pneumoniae / Q000187:drug effects
chemical_list: D000890:Anti-Infective Agents; D002969:Clavulanic Acids; D024841:Fluoroquinolones; D015363:Quinolones; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; C061363:sparfloxacin